Ocuphire Pharma, Inc. (OCUP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
37000 Grand River Avenue
Farmington Hills, MI 48335
United States of America (the)
Phone
248 681 9815
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
November 10, 2005
| Name | Title | Pay | Year Born |
| George Magrath | Chief Executive Officer & Director | 625,071 | 1984 |
| Jay S. Pepose | Chief Medical Advisor & Director | 392,000 | 1955 |
| Amy Zaremba Rabourn | Senior Vice President of Finance | 434,100 | 1981 |
| Bernhard Hoffmann | Senior Vice President of Corporate Development & Secretary | 434,100 | 1956 |
| Ashwath Jayagopal | Chief Scientific & Development Officer | 0 | 1982 |
| Joseph K. Schachle | Chief Operating Officer | 0 | 1965 |
| Erik Sims | Director & Corporate Controller | 0 | N/A |
| Nirav Suresh Jhaveri | Chief Financial Officer | 0 | 1978 |
| Bindu Manne | Head of Market Development & Commercialization | 0 | N/A |
Ocuphire Pharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to researching and bringing to market treatments for various refractive and retinal eye conditions. The company's primary investigational drug is Nyxol eye drops, a preservative-free phentolamine mesylate formulation administered once daily. Nyxol is currently undergoing advanced (Phase III) clinical trials for individuals experiencing difficulties with dim light or night vision. It is also in Phase 2b testing for reversing pharmacologically induced pupil dilation, and has successfully completed its Phase 2 VEGA-1 study for the treatment of presbyopia (age-related farsightedness). Beyond Nyxol, Ocuphire is developing APX3330, an oral tablet taken twice a day. This medication is designed to address key pathways involved in vascular diseases affecting the retina and choroid, including conditions like diabetic retinopathy and diabetic macular edema. Furthermore, the company is exploring APX2009 and APX2014, which are next-generation preclinical drug candidates and analogs derived from APX3330. Ocuphire Pharma, Inc. is based in Farmington Hills, Michigan.